Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

BLRX

BioLineRx (BLRX)

BioLineRx Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BLRX
DateTimeSourceHeadlineSymbolCompany
06/05/202421:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
17/04/202421:00PR Newswire (US)BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingNASDAQ:BLRXBioLineRx Ltd
04/03/202423:47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
28/02/202423:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
16/02/202423:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
08/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BLRXBioLineRx Ltd
30/12/202308:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLRXBioLineRx Ltd
30/12/202308:15Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BLRXBioLineRx Ltd
21/12/202323:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
12/12/202323:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
20/11/202323:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
20/11/202322:25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:BLRXBioLineRx Ltd
01/11/202322:43PR Newswire (Canada)BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
01/11/202300:00PR Newswire (US)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
01/11/202300:00PR Newswire (Canada)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
27/10/202305:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BLRXBioLineRx Ltd
19/10/202308:07AllPennyStocks.comNew Collaboration Could Revolutionize Treatment of Chronic Spinal Cord InjuriesNASDAQ:BLRXBioLineRx Ltd
12/10/202322:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
28/09/202321:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
11/09/202321:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
11/09/202321:00PR Newswire (US)BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaNASDAQ:BLRXBioLineRx Ltd
30/08/202321:16IH Market NewsWednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and moreNASDAQ:BLRXBioLineRx Ltd
30/08/202321:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
30/08/202320:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
09/08/202307:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
17/07/202321:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
24/06/202306:17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
24/05/202321:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
25/04/202321:08Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
18/04/202301:09Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
 Showing the most relevant articles for your search:NASDAQ:BLRX